MedTrace Logo

Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse

NCT04784221 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-09-17

No results posted yet for this study

Summary

This is a prospective multicenter non-randomized phase II study: proton therapy with nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously

Conditions

  • Recurrent Cancer
  • Previous Radiation

Interventions

RADIATION

Radiation by protontherapy associated to nanoparticles injection

Treatment for the study will be based on proton therapy and the administration of AGuIX® nanoparticles. Protontherapy will be carried out for 4 consecutive weeks with 5 sessions per week (20 sessions) from D1 to D26. The administration of the AGuIX® nanoparticle will be done on Days 1, 8 and 15 during protontherapy

Sponsors & Collaborators

  • Centre Francois Baclesse

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2027-09-30
Completion
2027-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04784221 on ClinicalTrials.gov